[go: up one dir, main page]

MX2019009419A - Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. - Google Patents

Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.

Info

Publication number
MX2019009419A
MX2019009419A MX2019009419A MX2019009419A MX2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A
Authority
MX
Mexico
Prior art keywords
compound
somatostatin receptor
agonistic activity
present
activity
Prior art date
Application number
MX2019009419A
Other languages
English (en)
Spanish (es)
Inventor
Yoshida Atsushi
Ishida Akiharu
Miyata Hidenori
SHONO Tomoyuki
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2019009419A publication Critical patent/MX2019009419A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2019009419A 2017-02-08 2018-02-07 Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. MX2019009419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017021363 2017-02-08
PCT/JP2018/004111 WO2018147300A1 (fr) 2017-02-08 2018-02-07 Composé ayant une activité agoniste du récepteur de la somatostatine et utilisation pharmaceutique associée

Publications (1)

Publication Number Publication Date
MX2019009419A true MX2019009419A (es) 2019-10-02

Family

ID=63108324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009419A MX2019009419A (es) 2017-02-08 2018-02-07 Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.

Country Status (15)

Country Link
US (1) US20200000816A1 (fr)
EP (1) EP3581569A4 (fr)
JP (1) JPWO2018147300A1 (fr)
KR (1) KR20190114986A (fr)
CN (1) CN110300749A (fr)
AU (1) AU2018219644A1 (fr)
BR (1) BR112019016433A2 (fr)
CA (1) CA3053091A1 (fr)
IL (1) IL268444A (fr)
MX (1) MX2019009419A (fr)
PH (1) PH12019501802A1 (fr)
RU (1) RU2019124888A (fr)
SG (1) SG11201907240XA (fr)
TW (1) TW201835081A (fr)
WO (1) WO2018147300A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269241B (en) 2017-03-16 2022-09-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
EP3752498B1 (fr) 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine et leurs utilisations
WO2019240246A1 (fr) * 2018-06-15 2019-12-19 小野薬品工業株式会社 Nouveaux sels et nouvelles formes cristallines de dérivés de pipéridinol
EP4548974A3 (fr) * 2018-09-18 2025-08-13 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine et leurs utilisations
CN109115914B (zh) * 2018-10-03 2021-06-04 四川中科微纳科技有限公司 一种分离盐酸雷莫司琼和其s型对映异构体的高效液相色谱方法
CN109115913B (zh) * 2018-10-03 2021-08-06 济南迪安医学检验中心有限公司 一种基于常规苯基色谱柱分离盐酸雷莫司琼和其s型对映异构体的hplc方法
JP7365094B2 (ja) * 2019-04-22 2023-10-19 株式会社Screenホールディングス 薬効評価方法、コンピュータプログラムおよび記録媒体
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
IL305011A (en) 2021-02-17 2023-10-01 Crinetics Pharmaceuticals Inc Crystalline forms of a somatostatin modulator
PE20251882A1 (es) * 2022-10-28 2025-07-22 Basecamp Bio Inc Agonistas del receptor de la somatostatina 2 y usos de estos
AU2023396827A1 (en) 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
MY123337A (en) 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (fr) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Derives d'amines
CO5261501A1 (es) 1999-11-10 2003-03-31 Takeda Pharmaceutical Derivados de acido pirazol-propionico y sus composiciones farmaceuticas
EP1285651B1 (fr) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
WO2002091125A2 (fr) 2001-05-07 2002-11-14 Ibiz Technology Corp. Boitier de protection et systeme de clavier pour un ordinateur tenant dans la main
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
WO2003042234A2 (fr) 2001-11-14 2003-05-22 Novartis Ag Ligands non peptidiques du recepteur de la somatostatine
MY133406A (en) 2001-11-28 2007-11-30 Ipsen Pharma Sas 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
PE20040837A1 (es) 2002-11-19 2004-12-24 Takeda Chemical Industries Ltd Compuestos de amina
AU2005223610B2 (en) * 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
JP2009155283A (ja) 2007-12-27 2009-07-16 Sumitomo Chemical Co Ltd オキサゾリジン化合物、オキサゾリドン化合物およびその中間体の製造方法
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
PT3053916T (pt) 2013-09-30 2019-03-26 Ono Pharmaceutical Co Composto com atividade agonista do recetor da somatostatina e utiliza ao farmaceutica do mesmo
EP3317278B1 (fr) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Modulateurs de somatostatine et leurs utilisations
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途

Also Published As

Publication number Publication date
IL268444A (en) 2019-09-26
EP3581569A4 (fr) 2020-02-19
TW201835081A (zh) 2018-10-01
KR20190114986A (ko) 2019-10-10
SG11201907240XA (en) 2019-09-27
CN110300749A (zh) 2019-10-01
JPWO2018147300A1 (ja) 2019-11-21
WO2018147300A1 (fr) 2018-08-16
PH12019501802A1 (en) 2020-03-02
AU2018219644A1 (en) 2019-08-29
RU2019124888A (ru) 2021-03-10
BR112019016433A2 (pt) 2020-04-07
EP3581569A1 (fr) 2019-12-18
US20200000816A1 (en) 2020-01-02
CA3053091A1 (fr) 2018-08-16

Similar Documents

Publication Publication Date Title
PH12019501802A1 (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
PH12020550680A1 (en) Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
EP4553071A3 (fr) Procédés d'amélioration de la mitophagie chez des sujets
NZ732507A (en) Improved compositions for treating muscular dystrophy
WO2015157559A3 (fr) Saxitoxines 10',11'-modifiées pour le traitement de la douleur
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
ZA202306172B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
ME02841B (fr) Pipéridyl-éthyl-pyrimidine substituée utilisée comme inhibiteur de la ghréline o-acyl transférase
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
PH12016502353A1 (en) Pharmaceutical composition
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
WO2018005801A3 (fr) Nouveaux agonistes de tgr5 non systémiques
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2018005794A3 (fr) Nouveaux agonistes de tgr5 non systémiques
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4